ENVB: Enveric Biosciences, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 5.51
Enterprise Value ($M) 3.22
Book Value ($M) 1.96
Book Value / Share 0.36
Price / Book 2.81
NCAV ($M) 1.24
NCAV / Share 0.23
Price / NCAV 4.45

Profitability (mra)
Return on Invested Capital (ROIC) -8.84
Return on Assets (ROA) -0.88
Return on Equity (ROE) -1.11

Liquidity (mrq)
Quick Ratio 1.53
Current Ratio 1.53

Balance Sheet (mrq) ($M)
Current Assets 3.58
Assets 4.30
Liabilities 2.34
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -16.45
Net Income -17.29
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -14.09
Cash from Investing 0.01
Cash from Financing -1.34

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
02-14 13G Armistice Capital, Llc 9.99
02-06 13G/A Intracoastal Capital, Llc 6.20 -29.66
02-05 13G/A Hudson Bay Capital Management LP 4.54 0.00

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-03-26 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the annual period ended: December 31, 2023 ☐ Transition Report Pursuant to Se
2023-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: September 30, 2023 ☐ Transition Report Pursuan
2023-08-11 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: June 30, 2023 ☐ Transition Report Pursuant to
2023-06-09 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the annual period ended: December 31, 2022 ☐ Transition R
2023-05-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: March 31, 2023 ☐ Transition Report Pursuant to
2023-03-31 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the annual period ended: December 31, 2022 ☐ Transition Report Pursuant to Se

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-03-28 40,195 248,917 16.15
2024-03-27 93,593 369,471 25.33
2024-03-26 45,728 262,436 17.42
2024-03-25 121,424 445,030 27.28

(click for more detail)

Similar Companies
ENLV – Enlivex Therapeutics Ltd. ENSC – Ensysce Biosciences, Inc.
ENTX – Entera Bio Ltd. EPIX – ESSA Pharma Inc.
EQ – Equillium, Inc.


Financial data and stock pages provided by
Fintel.io